Tempest licenses Senlang CAR-T platform, reports Q3 2026 results
Tempest exercised its option for exclusive rights to Senlang's CD7-targeted in vivo CAR-T platform and reported $0.9 million in cash with going concern doubt.
SEC filing
8 stories
Tempest exercised its option for exclusive rights to Senlang's CD7-targeted in vivo CAR-T platform and reported $0.9 million in cash with going concern doubt.
SEC filing
The move follows early Phase 1 data in 13 relapsed/refractory multiple myeloma patients treated with lead candidate TPST-4903.
SEC filing
Tempest received a Nasdaq deficiency letter on November 4, 2026 after its shares closed below $1.00 for 30 straight business days, starting a 180-day clock to fix it.
SEC filing
The Brisbane biotech disclosed a same-day CFO transition effective October 26, 2026, with the incoming finance chief working under a consulting engagement at $450 per hour.
SEC filing
The clinical-stage CAR-T company named the former Skillsoft CFO as a Class III director effective October 13, 2026.
SEC filing
Tempest Therapeutics raised $7.5 million through pre-funded warrants and common stock purchase warrants in an offering first sold September 15, 2026.
SEC filing
The Brisbane biotech named Nancy Freda-Smith to its board and Constance Ames as CFO while signing a $5 million-a-year services pact with CEO-linked Factor Bioscience.
SEC filing
The option, signed September 14, 2026, covers a BCMA/GPRC5D dual-targeting candidate now in Phase 1 for relapsed/refractory multiple myeloma.
SEC filing (2)